171 related articles for article (PubMed ID: 31192580)
1. Co-Delivery of Natural Compounds with a Dual-Targeted Nanoparticle Delivery System for Improving Synergistic Therapy in an Orthotopic Tumor Model.
Chu PY; Tsai SC; Ko HY; Wu CC; Lin YH
ACS Appl Mater Interfaces; 2019 Jul; 11(27):23880-23892. PubMed ID: 31192580
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional nanoparticles for targeting the tumor microenvironment to improve synergistic drug combinations and cancer treatment effects.
Chen ML; Lai CJ; Lin YN; Huang CM; Lin YH
J Mater Chem B; 2020 Dec; 8(45):10416-10427. PubMed ID: 33112350
[TBL] [Abstract][Full Text] [Related]
3. The Development of Hyaluronan/Fucoidan-Based Nanoparticles as Macrophages Targeting an Epigallocatechin-3-Gallate Delivery System.
Ho CH; Chu PY; Peng SL; Huang SC; Lin YH
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878305
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells.
Eom DW; Lee JH; Kim YJ; Hwang GS; Kim SN; Kwak JH; Cheon GJ; Kim KH; Jang HJ; Ham J; Kang KS; Yamabe N
BMB Rep; 2015 Aug; 48(8):461-6. PubMed ID: 25441423
[TBL] [Abstract][Full Text] [Related]
5. Targeted intracellular protein delivery based on hyaluronic acid-green tea catechin nanogels.
Liang K; Ng S; Lee F; Lim J; Chung JE; Lee SS; Kurisawa M
Acta Biomater; 2016 Mar; 33():142-52. PubMed ID: 26785145
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice.
Stearns ME; Amatangelo MD; Varma D; Sell C; Goodyear SM
Am J Pathol; 2010 Dec; 177(6):3169-79. PubMed ID: 20971741
[TBL] [Abstract][Full Text] [Related]
7. Carrier-Enhanced Anticancer Efficacy of Sunitinib-Loaded Green Tea-Based Micellar Nanocomplex beyond Tumor-Targeted Delivery.
Yongvongsoontorn N; Chung JE; Gao SJ; Bae KH; Yamashita A; Tan MH; Ying JY; Kurisawa M
ACS Nano; 2019 Jul; 13(7):7591-7602. PubMed ID: 31262169
[TBL] [Abstract][Full Text] [Related]
8. Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer.
Shukla R; Chanda N; Zambre A; Upendran A; Katti K; Kulkarni RR; Nune SK; Casteel SW; Smith CJ; Vimal J; Boote E; Robertson JD; Kan P; Engelbrecht H; Watkinson LD; Carmack TL; Lever JR; Cutler CS; Caldwell C; Kannan R; Katti KV
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12426-31. PubMed ID: 22802668
[TBL] [Abstract][Full Text] [Related]
9. (-)-Epigallocatechin gallate (EGCG)-nanoethosomes as a transdermal delivery system for docetaxel to treat implanted human melanoma cell tumors in mice.
Liao B; Ying H; Yu C; Fan Z; Zhang W; Shi J; Ying H; Ravichandran N; Xu Y; Yin J; Jiang Y; Du Q
Int J Pharm; 2016 Oct; 512(1):22-31. PubMed ID: 27544847
[TBL] [Abstract][Full Text] [Related]
10. Design and construction of IR780- and EGCG-based and mitochondrial targeting nanoparticles and their application in tumor chemo-phototherapy.
Bao J; Zhao Y; Xu J; Guo Y
J Mater Chem B; 2021 Dec; 9(48):9932-9945. PubMed ID: 34842269
[TBL] [Abstract][Full Text] [Related]
11. Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo.
Lee SC; Chan WK; Lee TW; Lam WH; Wang X; Chan TH; Wong YC
Nutr Cancer; 2008; 60(4):483-91. PubMed ID: 18584482
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Homing Cell-Penetrating Peptide Linked to Colloidal Mesoporous Silica Encapsulated (-)-Epigallocatechin-3-gallate as Drug Delivery System for Breast Cancer Therapy in Vivo.
Ding J; Yao J; Xue J; Li R; Bao B; Jiang L; Zhu JJ; He Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18145-55. PubMed ID: 26225796
[TBL] [Abstract][Full Text] [Related]
13. [Preparation, activity and targeting ability evaluation in vitro on folate mediated epigallocatechin-3-gallate albumin nanoparticles].
Zu YG; Yuan S; Zhao XH; Zhang Y; Zhang XN; Jiang R
Yao Xue Xue Bao; 2009 May; 44(5):525-31. PubMed ID: 19618731
[TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin Gallate/Layered Double Hydroxide Nanohybrids: Preparation, Characterization, and In Vitro Anti-Tumor Study.
Shafiei SS; Solati-Hashjin M; Samadikuchaksaraei A; Kalantarinejad R; Asadi-Eydivand M; Abu Osman NA
PLoS One; 2015; 10(8):e0136530. PubMed ID: 26317853
[TBL] [Abstract][Full Text] [Related]
15. Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3- gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles.
Wang R; Huang J; Chen J; Yang M; Wang H; Qiao H; Chen Z; Hu L; Di L; Li J
Nanomedicine; 2019 Oct; 21():102068. PubMed ID: 31374249
[TBL] [Abstract][Full Text] [Related]
16. Targeting Tumor Cells with Nanoparticles for Enhanced Co-Drug Delivery in Cancer Treatment.
Huang WY; Lai CH; Peng SL; Hsu CY; Hsu PH; Chu PY; Feng CL; Lin YH
Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575403
[TBL] [Abstract][Full Text] [Related]
17. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
[TBL] [Abstract][Full Text] [Related]
18. Desirable PEGylation for improving tumor selectivity of hyaluronic acid-based nanoparticles via low hepatic captured, long circulation times and CD44 receptor-mediated tumor targeting.
Teng C; Chai Z; Yuan Z; Ren L; Lin C; Yan Z; He W; Qin C; Yang L; Han X; Yin L
Nanomedicine; 2020 Feb; 24():102105. PubMed ID: 31740406
[TBL] [Abstract][Full Text] [Related]
19. Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy.
Sanna V; Singh CK; Jashari R; Adhami VM; Chamcheu JC; Rady I; Sechi M; Mukhtar H; Siddiqui IA
Sci Rep; 2017 Feb; 7():41573. PubMed ID: 28145499
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
Yan J; Wang Y; Jia Y; Liu S; Tian C; Pan W; Liu X; Wang H
Biomed Pharmacother; 2017 Apr; 88():374-383. PubMed ID: 28122302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
